A 52-year-old man with type 2 diabetes and dyslipidemia is started on a statin for primary prevention of cardiovascular disease. Which is the most common adverse effect that may limit long-term compliance with statin therapy?

Explanation

## Most Common Adverse Effect of Statins **Key Point:** Statin-associated muscle symptoms (SAMS), including myalgia and myopathy without significant elevation of creatine kinase (CK), are the most frequent dose-limiting adverse effects reported in clinical practice, occurring in 5–10% of patients on statin therapy. ### Frequency of Statin-Related Adverse Effects | Adverse Effect | Incidence | Severity | Clinical Significance | |---|---|---|---| | Muscle pain/weakness (SAMS) without elevated CK | 5–10% | Mild to moderate | Most common; limits compliance | | Elevated transaminases (>3× ULN) | 1–3% | Usually mild; reversible | Rare; often asymptomatic | | Statin-induced myopathy (elevated CK) | 0.1–0.5% | Moderate | Less common than SAMS | | Rhabdomyolysis | <0.01% | Severe; life-threatening | Extremely rare | | Acute kidney injury | <0.1% | Variable | Uncommon; usually with severe myopathy | ### Clinical Pearl **Clinical Pearl:** Statin-associated muscle symptoms (SAMS) are the leading reason for statin discontinuation in primary care, even though CK elevation is absent in most cases. This dissociation between symptoms and laboratory markers makes SAMS diagnosis challenging and is a key exam concept. ### Mechanism Statin-induced muscle symptoms likely involve: 1. Inhibition of ubiquinone (CoQ₁₀) synthesis in mitochondria 2. Impaired energy metabolism in muscle cells 3. Increased oxidative stress and inflammation 4. Genetic predisposition (polymorphisms in SLCO1B1 gene) ### High-Yield Facts **High-Yield:** - SAMS occurs WITHOUT significant CK elevation in ~90% of cases - Hepatotoxicity is rare and usually asymptomatic; routine LFT monitoring is not recommended - True statin-induced myopathy (CK >4× ULN + symptoms) is uncommon - Rhabdomyolysis is a medical emergency but represents <0.01% of statin users ### Management of SAMS 1. Dose reduction or temporary discontinuation 2. Switch to alternative statin (pravastatin, rosuvastatin less myopathy-prone) 3. Intermittent dosing (e.g., every other day) 4. CoQ₁₀ supplementation (evidence mixed but often tried) 5. Re-challenge with lower dose after symptom resolution [cite:KD Tripathi 8e Ch 31]